Home » Stocks » XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. (XTLB)

Stock Price: $1.65 USD 0.02 (1.23%)
Updated Aug 5, 2020 9:55 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 8.48M
Revenue (ttm) n/a
Net Income (ttm) -1.35M
Shares Out 5.14M
EPS (ttm) -1.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 5, 2020
Last Price $1.65
Previous Close $1.63
Change ($) 0.02
Change (%) 1.23%
Day's Open 1.63
Day's Range 1.65 - 1.65
Day's Volume 1,913
52-Week Range 0.62 - 2.10

More Stats

Market Cap 8.48M
Enterprise Value 1.76M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 5.14M
Float 3.09M
EPS (basic) -0.3
EPS (diluted) -1.00
FCF / Share -0.18
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5,472
Short Ratio 0.35
Short % of Float n/a
Beta 0.61
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.16
Revenue n/a
Operating Income -842,000
Net Income -1.35M
Free Cash Flow -910,000
Net Cash 6.73M
Net Cash / Share 1.31
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -5.71%
ROE -54.04%
ROIC -36.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$30.00*
Low
30.0
Current: $1.65
High
30.0
Target: 30.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----------
Operating Income-0.84-0.79-1.25-2.56-3.61-2.02-0.35-1.74-1.22-1.26
Net Income-1.352.99-0.78-2.55-4.31-2.53-3.71-1.74-1.21-1.26
Shares Outstanding51451447027426423144.7240.8138.3411.71
Earnings Per Share-0.300.60-0.20-0.90-1.70-1.10-5.50-3.00-3.00-5.50
Operating Cash Flow-0.91-0.82-1.13-1.73-1.86-2.47-2.50-1.51-1.31-0.74
Capital Expenditures------0.01-0.08-0.01-0.01-0.02
Free Cash Flow-0.91-0.82-1.12-1.73-1.86-2.48-2.58-1.51-1.32-0.75
Cash & Equivalents6.738.126.092.434.072.164.173.311.501.07
Net Cash / Debt6.738.126.092.434.072.164.173.311.501.07
Assets7.218.586.593.025.325.648.0211.094.073.80
Liabilities0.230.252.970.330.440.971.231.660.630.96
Book Value6.988.323.622.694.894.666.277.353.442.83
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name XTL Biopharmaceuticals Ltd.
Country Israel
CEO Shlomo Spokone Shalev

Stock Information

Ticker Symbol XTLB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: XTLB
IPO Date September 1, 2005

Description

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel.